Author Correction: Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis

EMBO Rep. 2025 Jun;26(12):3226-3227. doi: 10.1038/s44319-025-00478-6.

Amal M El-Naggar^{1

2

3}, Syam Prakash Somasekharan^#⁴, Yemin Wang^#², Hongwei Cheng^#⁴, Gian Luca Negri^#⁵, Melvin Pan², Xue Qi Wang², Alberto Delaidelli^{1

2}, Bo Rafn², Jordan Cran², Fan Zhang⁴, Haifeng Zhang^{1

2}, Shane Colborne⁵, Martin Gleave⁴, Anna Mandinova⁶, Nancy Kedersha⁷, Christopher S Hughes², Didier Surdez⁸, Olivier Delattre⁸, Yuzhuo Wang⁴, David G Huntsman^{1

2}, Gregg B Morin⁵, Poul H Sorensen^{9

10}

¹ Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
² Department of Molecular Oncology, BC Cancer, part of the Provincial Health Services Authority, Vancouver, BC, V5Z1L3, Canada.
³ Department of Pathology, Faculty of Medicine, Menoufia University, Shibin Al Kawm, Egypt.
⁴ Vancouver Prostate Centre, Vancouver, BC, V5Z 1M9, Canada.
⁵ Michael Smith Genome Sciences Centre, Vancouver, BC, V5Z4S6, Canada.
⁶ Brigham and Women's Hospital, Harvard University, Boston, MA, 02115, USA.
⁷ Massachusetts General Hospital, Harvard University, Boston, MA, 02114, USA.
⁸ Centre de recherche de l'Institut Curie, 75005, Paris, France.
⁹ Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada. psor@mail.ubc.ca.
¹⁰ Department of Molecular Oncology, BC Cancer, part of the Provincial Health Services Authority, Vancouver, BC, V5Z1L3, Canada. psor@mail.ubc.ca.

^# Contributed equally.

Abstract